Last reviewed · How we verify
Split thickness skin graft — Competitive Intelligence Brief
marketed
Wound Care / Dermatology / Regenerative Medicine
Biologic
Live · refreshed every 30 min
Target snapshot
Split thickness skin graft (Split thickness skin graft) — CellTherX. A split thickness skin graft is a surgical tissue transplant that replaces damaged or missing skin by transferring a partial-thickness layer of healthy skin from a donor site to the wound area.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Split thickness skin graft TARGET | Split thickness skin graft | CellTherX | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Split thickness skin graft CI watch — RSS
- Split thickness skin graft CI watch — Atom
- Split thickness skin graft CI watch — JSON
- Split thickness skin graft alone — RSS
Cite this brief
Drug Landscape (2026). Split thickness skin graft — Competitive Intelligence Brief. https://druglandscape.com/ci/split-thickness-skin-graft. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing